pyrimethamine has been researched along with Birth Weight in 42 studies
Maloprim: contains above 2 cpds
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adequate prevention regimen with monthly sulfadoxine-pyrimethamine given to all pregnant women has been proved to reduce the risk of LBW in malaria endemic areas." | 9.69 | Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial. ( Derra, K; Donnen, P; Dramaix, M; Kaboré, B; Lingani, M; Robert, A; Rouamba, T; Samadoulougou, S; Sanou, M; Somé, G; Sorgho, H; Tahita, MC; Tinto, H; Valéa, I; Zango, SH, 2023) |
| "Trials of intermittent preventive treatment (IPTp) of malaria in pregnant women that compared dihydroartemisinin-piperaquine with the standard of care, sulfadoxine-pyrimethamine, showed dihydroartemisinin-piperaquine was superior at preventing malaria infection, but not at improving birthweight." | 9.34 | Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. ( Chico, RM; Desai, M; Dorsey, G; Glymour, MM; Gosling, R; Gutman, J; Kajubi, R; Kakuru, A; Kamya, MR; Kuile, FOT; L'Ianziva, A; Rerolle, F; Roh, ME; Shiboski, S, 2020) |
| "The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)." | 9.12 | Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas." | 9.12 | Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. ( Fadero, FF; Falade, CO; Hamer, DH; Mokuolu, OA; Salako, LA; Yusuf, BO, 2007) |
| "This study highlights low adherence to the new 3-dose regimen of sulfadoxine-pyrimethamine-based intermittent preventive treatment in the Cotonou health zone II and III, but it reflects its potential to contribute to the reduction of the risk of low birth weight." | 7.91 | [Sulfadoxine-pyrimethamine-based intermittent preventive treatment in pregnant women and its effect on birth weight: application of 3-dosing regimen in the urban area of South Benin in 2017]. ( Ayivi-Vinz, G; Azandjèmé, C; Biaou, COA; Glèlè-Ahanhanzo, Y; Kpozehouen, A; Ouro-Koura, AR, 2019) |
| "Birth weight data from three regions in Democratic Republic of Congo with varying degrees of sulfadoxine-pyrimethamine (SP) resistance (1." | 7.78 | Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC). ( D'Alessandro, U; Dramaix, MW; Likwela, JL; Lokwa, BL; Meuris, S, 2012) |
| "To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome." | 7.75 | Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, PN; Msyamboza, KP; Savage, EJ, 2009) |
| "To monitor the effectiveness of intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) for the control of malaria in pregnancy at delivery in the Provincial Hospital in Kisumu, Kenya, and to assess the effect of IPT in participants in a cohort study." | 7.72 | Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. ( Ayisi, JG; Kager, PA; Misore, AO; Nahlen, BL; Odondi, JO; Otieno, JA; Rosen, DH; Steketee, RW; ter Kuile, FO; van Eijk, AM, 2004) |
| "The prevalence of infection with malarial parasites and the incidence of anaemia and delivery of infants with low birthweight (LBW) were investigated in 575 Malawian mothers who received one, two or three doses of sulfadoxine-pyrimethamine (SP) during pregnancy." | 7.70 | An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Kazembe, P; Russell, WB; Verhoeff, FH, 1998) |
| "Low birth weight was defined as weight < 2500 g irrespective of the gestational age of the foetus, while normal birth weight was between 2500 g to < 4000 g and macrosomia was = > 4000 g." | 5.72 | Predicting the effect of sulfadoxine-pyrimethamine uptake by pregnant women on birth weight using a generalized ordered partial proportional odds model. ( Afagbedzi, S; Guure, C, 2022) |
| "Adequate prevention regimen with monthly sulfadoxine-pyrimethamine given to all pregnant women has been proved to reduce the risk of LBW in malaria endemic areas." | 5.69 | Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial. ( Derra, K; Donnen, P; Dramaix, M; Kaboré, B; Lingani, M; Robert, A; Rouamba, T; Samadoulougou, S; Sanou, M; Somé, G; Sorgho, H; Tahita, MC; Tinto, H; Valéa, I; Zango, SH, 2023) |
| " Sulfadoxine-pyrimethamine (SP), given for intermittent preventive therapy of malaria in pregnancy (IPTp), is one of few existing interventions that improves outcomes of both mother and baby despite widespread SP-resistant malaria." | 5.51 | The positive effect of malaria IPTp-SP on birthweight is mediated by gestational weight gain but modifiable by maternal carriage of enteric pathogens. ( Bartelt, LA; Carroll, I; Chinkhumba, J; Gutman, JR; Itoh, M; Juliano, JJ; Kayange, M; Mathanga, DP; McQuade, ETR; Meshnick, SR; Mzembe, E; Operario, DJ; Puerto-Meredith, SM; Waltmann, A, 2022) |
| "Sulfadoxine-pyrimethamine (SP) is used as intermittent preventive therapy in pregnancy (IPTp) for malaria in sub-Saharan Africa." | 5.34 | Interactions Between Antenatal Sulfadoxine-Pyrimethamine, Drug-Resistant Plasmodium falciparum Parasites, and Delivery Outcomes in Malawi. ( Freedman, B; Kalilani-Phiri, L; Khairallah, C; Levitt, B; Madanitsa, M; Meshnick, SR; Mwapasa, V; Taylor, SM; Ter Kuile, FO; Thwai, KL, 2020) |
| "Trials of intermittent preventive treatment (IPTp) of malaria in pregnant women that compared dihydroartemisinin-piperaquine with the standard of care, sulfadoxine-pyrimethamine, showed dihydroartemisinin-piperaquine was superior at preventing malaria infection, but not at improving birthweight." | 5.34 | Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. ( Chico, RM; Desai, M; Dorsey, G; Glymour, MM; Gosling, R; Gutman, J; Kajubi, R; Kakuru, A; Kamya, MR; Kuile, FOT; L'Ianziva, A; Rerolle, F; Roh, ME; Shiboski, S, 2020) |
| "Intermittent preventive treatment in pregnancy (IPTp) with azithromycin and monthly sulfadoxine-pyrimethamine increased the mean child weight, mid-upper arm and head circumference at four weeks of age in a rural low-income setting." | 5.30 | The impact of maternal antenatal treatment with two doses of azithromycin and monthly sulphadoxine-pyrimethamine on child weight, mid-upper arm circumference and head circumference: A randomized controlled trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Hallamaa, L; Kulmala, T; Luntamo, M; Mangani, C, 2019) |
| "The efficacy of intermittent preventive treatment for malaria with sulfadoxine-pyrimethamine (IPTp-SP) in pregnancy is threatened in parts of Africa by the emergence and spread of resistance to SP." | 5.20 | A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy. ( Abubakar, I; Akor, F; Awine, T; Bationo, R; Bojang, K; Cairns, M; Chandramohan, D; Coulibaly, SO; Dabira, E; Djimdé, M; Doumbo, O; Greenwood, B; Guirou, E; Hodgson, A; Kayentao, K; Magnussen, P; Meshnick, S; Milligan, P; Mohammed, K; Njie, F; Oduro, A; Ordi, J; Quaye, S; Soulama, A; Tagbor, H; Taylor, S; ter Kuile, F; Williams, J; Woukeu, A, 2015) |
| "To examine the potential to reduce foetal and neonatal growth faltering through intermittent preventive treatment in pregnancy (IPTp) of malaria and reproductive tract infections with monthly sulphadoxine-pyrimethamine (SP), alone or with two doses of azithromycin." | 5.17 | The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. ( Ashorn, P; Cheung, YB; Kulmala, T; Luntamo, M; Maleta, K, 2013) |
| "To investigate the consequences of intermittent preventive treatment (IPTp) timing on birth weight, we pooled data from two studies conducted in Benin between 2005 and 2010: a prospective cohort of 1037 pregnant women and a randomised trial comparing sulfadoxine-pyrimethamine (SP) to mefloquine in 1601 women." | 5.16 | Consequences of gestational malaria on birth weight: finding the best timeframe for intermittent preventive treatment administration. ( Borgella, S; Briand, V; Cot, M; Deloron, P; Fievet, N; Huynh, BT; Massougbodji, A, 2012) |
| "Few studies have documented the effectiveness in west Africa of intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine (SP) in pregnancy." | 5.12 | A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women. ( Madaki, JK; Sagay, AS; Thacher, TD; Tukur, IU, 2007) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas." | 5.12 | Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. ( Fadero, FF; Falade, CO; Hamer, DH; Mokuolu, OA; Salako, LA; Yusuf, BO, 2007) |
| "The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)." | 5.12 | Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "In Mali, IPT with SP appears more efficacious than weekly chloroquine chemoprophylaxis in preventing malaria during pregnancy." | 5.11 | Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. ( Coulibaly, D; Doumbo, O; Doumtabe, D; Kayentao, K; Keita, AS; Kodio, M; Maiga, B; Maiga, H; Mungai, M; Newman, RD; Ongoiba, A; Parise, ME, 2005) |
| "Intermittent preventive therapy during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in areas of moderate to high malaria transmission intensity." | 4.31 | Peripheral and Placental Prevalence of Sulfadoxine-Pyrimethamine Resistance Markers in Plasmodium falciparum among Pregnant Women in Southern Province, Rwanda. ( Abram, A; Alruwaili, M; Eckert, E; Gutman, JR; Mbituyumuremyi, A; Munguti, K; Murindahabi, M; Piercefield, E; Sethi, R; Sullivan, DJ; Umulisa, N; Uwimana, A, 2023) |
| "Mutations in the Plasmodium falciparum genes Pfdhfr and Pfdhps, particularly the sextuple mutant haplotype threatens the antimalarial effectiveness of sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment during pregnancy (IPTp)." | 4.02 | Reduced Birth Weight Caused by Sextuple Drug-Resistant Plasmodium falciparum Infection in Early Second Trimester. ( Alifrangis, M; Bygbjerg, IC; Hansson, H; Jensen, RW; Lusingu, JPA; Minja, DTR; Moeller, SL; Msemo, OA; Nag, S; Schmiegelow, C; Theander, TG; Yde, AM, 2021) |
| "A cross-sectional study was conducted of 426 pregnant mothers on IPTp with sulphadoxine-pyrimethamine against malaria who presented in labor, at National Hospital Abuja, Nigeria between January and June 2017." | 3.96 | The efficacy of intermittent preventive therapy in the eradication of peripheral and placental parasitemia in a malaria-endemic environment, as seen in a tertiary hospital in Abuja, Nigeria. ( Agboghoroma, CO; Iregbu, KC; Umemmuo, MU, 2020) |
| "Despite the clinically proven advantages of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), utilisation has been low in many African countries." | 3.91 | High uptake of Intermittent Preventive Treatment of malaria in pregnancy is associated with improved birth weight among pregnant women in Ghana. ( Anang, AK; Asare, GQ; Coleman, N; Cot, M; Cottrell, G; Deloron, P; Escriou, G; Fobil, J; Houze, P; Kusi, KA; Laar, A; Ndam, NT; Ofori, MF; Quakyi, I; Tornyigah, B, 2019) |
| "This study highlights low adherence to the new 3-dose regimen of sulfadoxine-pyrimethamine-based intermittent preventive treatment in the Cotonou health zone II and III, but it reflects its potential to contribute to the reduction of the risk of low birth weight." | 3.91 | [Sulfadoxine-pyrimethamine-based intermittent preventive treatment in pregnant women and its effect on birth weight: application of 3-dosing regimen in the urban area of South Benin in 2017]. ( Ayivi-Vinz, G; Azandjèmé, C; Biaou, COA; Glèlè-Ahanhanzo, Y; Kpozehouen, A; Ouro-Koura, AR, 2019) |
| "Six years after the implementation of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) in Gabon, its impact on placental malaria and pregnancy outcomes remains unknown." | 3.83 | Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon. ( Ambounda, N; Bouyou-Akotet, MK; Kendjo, E; Kombila, M; Mawili-Mboumba, DP; Moutandou Chiesa, S; Tshibola Mbuyi, ML; Tsoumbou-Bakana, G; Zong, J, 2016) |
| "Birth weight data from three regions in Democratic Republic of Congo with varying degrees of sulfadoxine-pyrimethamine (SP) resistance (1." | 3.78 | Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC). ( D'Alessandro, U; Dramaix, MW; Likwela, JL; Lokwa, BL; Meuris, S, 2012) |
| "To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome." | 3.75 | Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, PN; Msyamboza, KP; Savage, EJ, 2009) |
| "Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) has been adopted as policy by many countries in sub-Saharan Africa." | 3.74 | Decline of placental malaria in southern Ghana after the implementation of intermittent preventive treatment in pregnancy. ( Acquah, PA; Bedu-Addo, G; Bienzle, U; Eggelte, TA; Holmberg, V; Hommerich, L; Mockenhaupt, FP; von Oertzen, C, 2007) |
| "To monitor the effectiveness of intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) for the control of malaria in pregnancy at delivery in the Provincial Hospital in Kisumu, Kenya, and to assess the effect of IPT in participants in a cohort study." | 3.72 | Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. ( Ayisi, JG; Kager, PA; Misore, AO; Nahlen, BL; Odondi, JO; Otieno, JA; Rosen, DH; Steketee, RW; ter Kuile, FO; van Eijk, AM, 2004) |
| "The prevalence of infection with malarial parasites and the incidence of anaemia and delivery of infants with low birthweight (LBW) were investigated in 575 Malawian mothers who received one, two or three doses of sulfadoxine-pyrimethamine (SP) during pregnancy." | 3.70 | An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Kazembe, P; Russell, WB; Verhoeff, FH, 1998) |
| " However, the optimal dosing regimen in settings in which human immunodeficiency virus (HIV) is highly prevalent among pregnant women remains controversial." | 2.73 | Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mubikayi, L; Mukwamataba, D; Mulele, CK; Mulenga, M; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "Low birth weight was defined as weight < 2500 g irrespective of the gestational age of the foetus, while normal birth weight was between 2500 g to < 4000 g and macrosomia was = > 4000 g." | 1.72 | Predicting the effect of sulfadoxine-pyrimethamine uptake by pregnant women on birth weight using a generalized ordered partial proportional odds model. ( Afagbedzi, S; Guure, C, 2022) |
| "007) and dosage (p = 0." | 1.72 | Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi ( Achidi, EA; Amambua-Ngwa, A; Anchang-Kimbi, JK; Apinjoh, TO; Chi, HF; Dionne-Odom, J; Kwi, PN; Mayaba, JM; Moyeh, MN; Ntui, VN; Tangi, LN; Tita, ATN; Titanji, VPK; Toussi, CT, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.76) | 18.7374 |
| 1990's | 2 (4.76) | 18.2507 |
| 2000's | 10 (23.81) | 29.6817 |
| 2010's | 15 (35.71) | 24.3611 |
| 2020's | 13 (30.95) | 2.80 |
| Authors | Studies |
|---|---|
| Menendez, C | 2 |
| Todd, J | 1 |
| Alonso, PL | 1 |
| Lulat, S | 1 |
| Francis, N | 1 |
| Greenwood, BM | 1 |
| Waltmann, A | 1 |
| McQuade, ETR | 1 |
| Chinkhumba, J | 1 |
| Operario, DJ | 1 |
| Mzembe, E | 1 |
| Itoh, M | 1 |
| Kayange, M | 1 |
| Puerto-Meredith, SM | 1 |
| Mathanga, DP | 1 |
| Juliano, JJ | 1 |
| Carroll, I | 1 |
| Bartelt, LA | 1 |
| Gutman, JR | 3 |
| Meshnick, SR | 3 |
| Guure, C | 1 |
| Afagbedzi, S | 1 |
| Apinjoh, TO | 1 |
| Ntui, VN | 1 |
| Chi, HF | 1 |
| Moyeh, MN | 1 |
| Toussi, CT | 1 |
| Mayaba, JM | 1 |
| Tangi, LN | 1 |
| Kwi, PN | 1 |
| Anchang-Kimbi, JK | 1 |
| Dionne-Odom, J | 1 |
| Tita, ATN | 1 |
| Achidi, EA | 1 |
| Amambua-Ngwa, A | 1 |
| Titanji, VPK | 1 |
| Ampofo, GD | 1 |
| Osarfo, J | 1 |
| Aberese-Ako, M | 1 |
| Asem, L | 1 |
| Komey, MN | 1 |
| Mohammed, W | 1 |
| Ofosu, AA | 1 |
| Tagbor, H | 2 |
| Crider, K | 1 |
| Williams, J | 2 |
| Qi, YP | 1 |
| Gutman, J | 2 |
| Yeung, L | 1 |
| Mai, C | 1 |
| Finkelstain, J | 1 |
| Mehta, S | 1 |
| Pons-Duran, C | 1 |
| Moraleda, C | 1 |
| Rogers, L | 1 |
| Daniels, K | 1 |
| Green, P | 1 |
| Uwimana, A | 2 |
| Sethi, R | 2 |
| Murindahabi, M | 2 |
| Ntirandeka, C | 1 |
| Piercefield, E | 2 |
| Umulisa, N | 2 |
| Abram, A | 2 |
| Eckert, E | 2 |
| Munguti, K | 2 |
| Sullivan, D | 1 |
| Uyizeye, D | 1 |
| Mbituyumuremyi, A | 2 |
| Lingani, M | 1 |
| Zango, SH | 1 |
| Valéa, I | 1 |
| Samadoulougou, S | 1 |
| Somé, G | 1 |
| Sanou, M | 1 |
| Kaboré, B | 1 |
| Rouamba, T | 1 |
| Sorgho, H | 1 |
| Tahita, MC | 1 |
| Derra, K | 1 |
| Dramaix, M | 1 |
| Tinto, H | 1 |
| Donnen, P | 1 |
| Robert, A | 1 |
| Alruwaili, M | 1 |
| Sullivan, DJ | 1 |
| Umemmuo, MU | 1 |
| Agboghoroma, CO | 1 |
| Iregbu, KC | 1 |
| Quakyi, I | 1 |
| Tornyigah, B | 1 |
| Houze, P | 1 |
| Kusi, KA | 1 |
| Coleman, N | 1 |
| Escriou, G | 1 |
| Laar, A | 1 |
| Cot, M | 2 |
| Fobil, J | 1 |
| Asare, GQ | 1 |
| Deloron, P | 2 |
| Anang, AK | 1 |
| Cottrell, G | 1 |
| Ofori, MF | 1 |
| Ndam, NT | 1 |
| Biaou, COA | 1 |
| Kpozehouen, A | 1 |
| Glèlè-Ahanhanzo, Y | 1 |
| Ayivi-Vinz, G | 1 |
| Ouro-Koura, AR | 1 |
| Azandjèmé, C | 1 |
| Taylor, SM | 2 |
| Levitt, B | 1 |
| Freedman, B | 1 |
| Madanitsa, M | 1 |
| Thwai, KL | 1 |
| Kalilani-Phiri, L | 1 |
| Khairallah, C | 1 |
| Mwapasa, V | 1 |
| Ter Kuile, FO | 3 |
| Salman, S | 1 |
| Davis, TME | 1 |
| Moore, B | 1 |
| Roh, ME | 1 |
| Kuile, FOT | 1 |
| Rerolle, F | 1 |
| Glymour, MM | 1 |
| Shiboski, S | 1 |
| Gosling, R | 1 |
| Kakuru, A | 1 |
| Desai, M | 1 |
| Kajubi, R | 1 |
| L'Ianziva, A | 1 |
| Kamya, MR | 1 |
| Dorsey, G | 1 |
| Chico, RM | 1 |
| Hansson, H | 1 |
| Minja, DTR | 1 |
| Moeller, SL | 1 |
| Lusingu, JPA | 1 |
| Bygbjerg, IC | 1 |
| Yde, AM | 1 |
| Jensen, RW | 1 |
| Nag, S | 1 |
| Msemo, OA | 1 |
| Theander, TG | 1 |
| Alifrangis, M | 2 |
| Schmiegelow, C | 1 |
| Cates, JE | 1 |
| Westreich, D | 1 |
| Unger, HW | 2 |
| Bauserman, M | 1 |
| Adair, L | 1 |
| Cole, SR | 1 |
| Meshnick, S | 2 |
| Rogerson, SJ | 2 |
| Hallamaa, L | 1 |
| Cheung, YB | 2 |
| Luntamo, M | 2 |
| Ashorn, U | 1 |
| Kulmala, T | 2 |
| Mangani, C | 1 |
| Ashorn, P | 2 |
| Maleta, K | 1 |
| Mosha, D | 1 |
| Chilongola, J | 1 |
| Ndeserua, R | 1 |
| Mwingira, F | 1 |
| Genton, B | 1 |
| Mbonye, AK | 1 |
| Birungi, J | 1 |
| Yanow, SK | 1 |
| Shokoples, S | 1 |
| Malamba, S | 1 |
| Magnussen, P | 2 |
| Cairns, M | 2 |
| Bojang, K | 1 |
| Coulibaly, SO | 2 |
| Kayentao, K | 2 |
| Abubakar, I | 1 |
| Akor, F | 1 |
| Mohammed, K | 1 |
| Bationo, R | 1 |
| Dabira, E | 1 |
| Soulama, A | 1 |
| Djimdé, M | 1 |
| Guirou, E | 1 |
| Awine, T | 1 |
| Quaye, S | 1 |
| Njie, F | 1 |
| Ordi, J | 1 |
| Doumbo, O | 2 |
| Hodgson, A | 1 |
| Oduro, A | 1 |
| Taylor, S | 1 |
| ter Kuile, F | 2 |
| Woukeu, A | 1 |
| Milligan, P | 1 |
| Chandramohan, D | 1 |
| Greenwood, B | 1 |
| Wangnapi, RA | 1 |
| Ome-Kaius, M | 1 |
| Boeuf, P | 1 |
| Karl, S | 1 |
| Mueller, I | 1 |
| Bouyou-Akotet, MK | 1 |
| Mawili-Mboumba, DP | 1 |
| Kendjo, E | 1 |
| Moutandou Chiesa, S | 1 |
| Tshibola Mbuyi, ML | 1 |
| Tsoumbou-Bakana, G | 1 |
| Zong, J | 1 |
| Ambounda, N | 1 |
| Kombila, M | 1 |
| Walker, PG | 1 |
| Floyd, J | 1 |
| Gies, S | 2 |
| Ouattara, FT | 1 |
| D'Alessandro, U | 3 |
| Msyamboza, KP | 1 |
| Savage, EJ | 1 |
| Kazembe, PN | 1 |
| Kalanda, G | 1 |
| Brabin, BJ | 2 |
| van Eijk, AM | 2 |
| Hand, CC | 1 |
| Mwandagalirwa, K | 1 |
| Messina, JP | 1 |
| Tshefu, AK | 1 |
| Atua, B | 1 |
| Emch, M | 1 |
| Muwonga, J | 1 |
| Likwela, JL | 1 |
| Lokwa, BL | 1 |
| Meuris, S | 1 |
| Dramaix, MW | 1 |
| Huynh, BT | 1 |
| Fievet, N | 1 |
| Briand, V | 1 |
| Borgella, S | 1 |
| Massougbodji, A | 1 |
| MORLEY, D | 1 |
| WOODLAND, M | 1 |
| CUTHBERTSON, WF | 1 |
| Ayisi, JG | 1 |
| Otieno, JA | 1 |
| Misore, AO | 1 |
| Odondi, JO | 1 |
| Rosen, DH | 1 |
| Kager, PA | 1 |
| Steketee, RW | 1 |
| Nahlen, BL | 1 |
| Challis, K | 1 |
| Osman, NB | 1 |
| Cotiro, M | 1 |
| Nordahl, G | 1 |
| Dgedge, M | 1 |
| Bergström, S | 1 |
| Kodio, M | 1 |
| Newman, RD | 1 |
| Maiga, H | 1 |
| Doumtabe, D | 1 |
| Ongoiba, A | 1 |
| Coulibaly, D | 1 |
| Keita, AS | 1 |
| Maiga, B | 1 |
| Mungai, M | 1 |
| Parise, ME | 1 |
| Tukur, IU | 1 |
| Thacher, TD | 1 |
| Sagay, AS | 1 |
| Madaki, JK | 1 |
| Falade, CO | 1 |
| Yusuf, BO | 1 |
| Fadero, FF | 1 |
| Mokuolu, OA | 1 |
| Hamer, DH | 3 |
| Salako, LA | 1 |
| Hommerich, L | 1 |
| von Oertzen, C | 1 |
| Bedu-Addo, G | 1 |
| Holmberg, V | 1 |
| Acquah, PA | 1 |
| Eggelte, TA | 1 |
| Bienzle, U | 1 |
| Mockenhaupt, FP | 1 |
| Gill, CJ | 2 |
| Macleod, WB | 2 |
| Mwanakasale, V | 2 |
| Chalwe, V | 2 |
| Mwananyanda, L | 2 |
| Champo, D | 2 |
| Mukwamataba, D | 2 |
| Chilengi, R | 2 |
| Thea, DM | 2 |
| Mubikayi, L | 1 |
| Mulele, CK | 1 |
| Mulenga, M | 1 |
| Verhoeff, FH | 1 |
| Chimsuku, L | 1 |
| Kazembe, P | 1 |
| Russell, WB | 1 |
| Broadhead, RL | 1 |
| Harrison, KA | 1 |
| Ibeziako, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon[NCT06173206] | Phase 3 | 900 participants (Anticipated) | Interventional | 2024-03-15 | Not yet recruiting | ||
| Prevention of Malaria in HIV-uninfected Pregnant Women and Infants[NCT02793622] | Phase 3 | 782 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin[NCT00131235] | Phase 3 | 1,320 participants (Actual) | Interventional | 2003-12-31 | Active, not recruiting | ||
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| A Trial of Intermittent Preventive Treatment With Sulfadoxine-pyrimethamine Versus Intermittent Screening and Treatment of Malaria in Pregnancy[NCT01084213] | Phase 4 | 5,354 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Assessing the Effectiveness of Community Delivery of Intermittent Preventive Treatment in Pregnancy (IPTp) in Malawi[NCT03376217] | 1,447 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia[NCT00270530] | Phase 4 | 454 participants | Interventional | 2002-11-30 | Completed | ||
| Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850] | Phase 3 | 2,793 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria. (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 44 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 24 |
Admission to the pediatric ward for any cause (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 19 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
episodes per person year (NCT02793622)
Timeframe: Time at risk will begin at birth and end when study participants reaches 12 months of age or early study termination
| Intervention | episodes per person year (Number) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 1.98 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1.71 |
Any deaths occurring after birth (NCT02793622)
Timeframe: Birth up to 12 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 9 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 |
Gestational age in weeks determined by ultrasound dating (gold standard) and by the metabolic profiling outcome from biological specimens including placental tissue and placental blood. (NCT02793622)
Timeframe: At the time of delivery
| Intervention | weeks (Mean) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 39.4 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 39.6 |
Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (< 2500 gm); 2) Preterm delivery (< 37 weeks gestational age); 3) Small for gestational age (< 10th percentile relative to an external growth reference) (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 60 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 54 |
All grade 3 and 4 adverse events (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 54 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 43 |
"Defined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age. Number of cases per person year (PPY).~This is a prevalence measure but are repeated measures during infancy. In other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age)." (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | routine hemoglobin measurement (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 222 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 216 |
hemoglobin < 11 g/dL (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | blood smears (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 344 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 357 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | blood smears (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 519 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 9 |
Maternal blood positive for malaria parasites by microscopy. (NCT02793622)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1 |
Any evidence of placental infection (parasites or pigment). Number of participants with placental tissue positive for malaria parasites or pigment. (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 197 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 94 |
Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| LAMP | Microscopy | |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 | 1 |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 71 | 29 |
2 reviews available for pyrimethamine and Birth Weight
| Article | Year |
|---|---|
Malaria in pregnancy control and pregnancy outcomes: a decade's overview using Ghana's DHIMS II data.
Topics: Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Ghana; Humans; Malaria; Pregnancy; P | 2022 |
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Topics: Anemia; Antimalarials; Birth Weight; Child; Child, Preschool; Dietary Supplements; Female; Folic Aci | 2022 |
17 trials available for pyrimethamine and Birth Weight
| Article | Year |
|---|---|
Malaria chemoprophylaxis, infection of the placenta and birth weight in Gambian primigravidae.
Topics: Acute Disease; Antimalarials; Birth Weight; Chronic Disease; Dapsone; Double-Blind Method; Drug Comb | 1994 |
The positive effect of malaria IPTp-SP on birthweight is mediated by gestational weight gain but modifiable by maternal carriage of enteric pathogens.
Topics: Antimalarials; Birth Weight; Cryptosporidiosis; Cryptosporidium; Drug Combinations; Escherichia coli | 2022 |
Effectiveness of Intermittent Screening and Treatment of Malaria in Pregnancy on Maternal and Birth Outcomes in Selected Districts in Rwanda: A Cluster Randomized Controlled Trial.
Topics: Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Pl | 2023 |
Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial.
Topics: Abortion, Spontaneous; Antimalarials; Azithromycin; Birth Weight; Burkina Faso; Drug Combinations; F | 2023 |
Interactions Between Antenatal Sulfadoxine-Pyrimethamine, Drug-Resistant Plasmodium falciparum Parasites, and Delivery Outcomes in Malawi.
Topics: Adolescent; Adult; Animals; Birth Weight; Drug Combinations; Drug Resistance; Female; Genotype; Huma | 2020 |
Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis.
Topics: Adult; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Newborn; Kenya; Malar | 2020 |
The impact of maternal antenatal treatment with two doses of azithromycin and monthly sulphadoxine-pyrimethamine on child weight, mid-upper arm circumference and head circumference: A randomized controlled trial.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Arm; Azithromycin; Birth Weight; Child; Child, Preschoo | 2019 |
The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Birth Weight; Drug Administra | 2013 |
A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Topics: Adolescent; Adult; Africa; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Gam | 2015 |
A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Topics: Adolescent; Adult; Africa; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Gam | 2015 |
A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Topics: Adolescent; Adult; Africa; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Gam | 2015 |
A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Topics: Adolescent; Adult; Africa; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Gam | 2015 |
Individual efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine in primi- and secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and birth weight.
Topics: Adult; Anemia; Animals; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Humans | 2009 |
Consequences of gestational malaria on birth weight: finding the best timeframe for intermittent preventive treatment administration.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Newborn; | 2012 |
Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Double-Blind Method; Drug Administration Schedule; D | 2004 |
Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anemia; Birth Weight; Chemoprevention; Chloroquine; Drug A | 2005 |
A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women.
Topics: Adult; Animals; Antimalarials; Birth Weight; Chloroquine; Drug Combinations; Female; Hematocrit; Hum | 2007 |
Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Dizziness; Drug Combinations; Female; Humans; Malari | 2007 |
Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth | 2007 |
Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth | 2007 |
23 other studies available for pyrimethamine and Birth Weight
| Article | Year |
|---|---|
Predicting the effect of sulfadoxine-pyrimethamine uptake by pregnant women on birth weight using a generalized ordered partial proportional odds model.
Topics: Adult; Antimalarials; Birth Weight; Demography; Drug Combinations; Female; Fetal Macrosomia; Ghana; | 2022 |
Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi
Topics: Antimalarials; Birth Weight; Cameroon; Drug Combinations; Female; Humans; Infant, Newborn; Insectici | 2022 |
Peripheral and Placental Prevalence of Sulfadoxine-Pyrimethamine Resistance Markers in Plasmodium falciparum among Pregnant Women in Southern Province, Rwanda.
Topics: Antimalarials; Birth Weight; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Malaria, F | 2023 |
The efficacy of intermittent preventive therapy in the eradication of peripheral and placental parasitemia in a malaria-endemic environment, as seen in a tertiary hospital in Abuja, Nigeria.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Cross-Sectional Studies; Drug Combinations; Female; | 2020 |
High uptake of Intermittent Preventive Treatment of malaria in pregnancy is associated with improved birth weight among pregnant women in Ghana.
Topics: Adolescent; Adult; Birth Weight; Cohort Studies; Drug Combinations; Female; Ghana; Humans; Linear Mo | 2019 |
[Sulfadoxine-pyrimethamine-based intermittent preventive treatment in pregnant women and its effect on birth weight: application of 3-dosing regimen in the urban area of South Benin in 2017].
Topics: Adult; Antimalarials; Benin; Birth Weight; Cross-Sectional Studies; Drug Combinations; Female; Human | 2019 |
Defining the combined benefit of intermittent preventive malaria treatment in pregnancy.
Topics: Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Malaria; Pregnancy; Pyrimethamine; S | 2020 |
Reduced Birth Weight Caused by Sextuple Drug-Resistant Plasmodium falciparum Infection in Early Second Trimester.
Topics: Adult; Antimalarials; Birth Weight; Drug Combinations; Drug Resistance; Female; Humans; Infant, Newb | 2021 |
Intermittent Preventive Therapy in Pregnancy and Incidence of Low Birth Weight in Malaria-Endemic Countries.
Topics: Africa; Antimalarials; Birth Weight; Female; Humans; Malaria; Malnutrition; Pregnancy; Pyrimethamine | 2018 |
Bigger babies for women given extra prophylaxis against malaria.
Topics: Africa South of the Sahara; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, | 2013 |
Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on placental malaria, maternal anaemia and birthweight in areas with high and low malaria transmission intensity in Tanzania.
Topics: Adult; Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Low Birth Wei | 2014 |
Prevalence of Plasmodium falciparum resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda.
Topics: Antimalarials; Bacterial Proteins; Birth Weight; Drug Combinations; Female; Humans; Malaria, Falcipa | 2015 |
Azithromycin-containing intermittent preventive treatment in pregnancy affects gestational weight gain, an important predictor of birthweight in Papua New Guinea - an exploratory analysis.
Topics: Adolescent; Antimalarials; Azithromycin; Birth Weight; Body Mass Index; Drug Combinations; Female; F | 2016 |
Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon.
Topics: Adult; Anemia; Antimalarials; Birth Weight; Cities; Cross-Sectional Studies; Drug Combinations; Fema | 2016 |
Estimated impact on birth weight of scaling up intermittent preventive treatment of malaria in pregnancy given sulphadoxine-pyrimethamine resistance in Africa: A mathematical model.
Topics: Africa South of the Sahara; Antimalarials; Birth Weight; Child; Child, Preschool; Drug Combinations; | 2017 |
Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi.
Topics: Adolescent; Adult; Anemia; Antimalarials; Birth Weight; Community Health Services; Drug Combinations | 2009 |
Quantification of the burden and consequences of pregnancy-associated malaria in the Democratic Republic of the Congo.
Topics: Anemia; Antimalarials; Birth Weight; Cross-Sectional Studies; Democratic Republic of the Congo; Drug | 2011 |
Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC).
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Congo; Drug Combinations; Drug Resistance; Female; F | 2012 |
CONTROLLED TRIAL OF PYRIMETHAMINE IN PREGNANT WOMEN IN AN AFRICAN VILLAGE.
Topics: Birth Weight; Chloroquine; Female; Humans; Infant; Infant Mortality; Lactose; Malaria; Nigeria; Preg | 1964 |
Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Birth Weight; Cohort Studies; Drug Admi | 2004 |
Decline of placental malaria in southern Ghana after the implementation of intermittent preventive treatment in pregnancy.
Topics: Adolescent; Adult; Anemia; Animals; Antimalarials; Birth Weight; Chemoprevention; Drug Administratio | 2007 |
An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Drug Therapy, Combination; Female; Humans; Infant, L | 1998 |
Maternal anaemia and fetal birthweight.
Topics: Anemia; Anemia, Sickle Cell; Birth Weight; Blood Transfusion; Body Height; Chloroquine; Embryonic an | 1973 |